1. Home
  2. BIOX vs ALLO Comparison

BIOX vs ALLO Comparison

Compare BIOX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioceres Crop Solutions Corp.

BIOX

Bioceres Crop Solutions Corp.

HOLD

Current Price

$1.40

Market Cap

109.2M

Sector

Industrials

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIOX
ALLO
Founded
2001
2017
Country
Argentina
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.2M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BIOX
ALLO
Price
$1.40
$1.43
Analyst Decision
Buy
Buy
Analyst Count
3
11
Target Price
$4.42
$8.67
AVG Volume (30 Days)
431.7K
2.5M
Earning Date
02-10-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$318,158,904.00
N/A
Revenue This Year
$1.25
N/A
Revenue Next Year
$27.91
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$0.86
52 Week High
$7.44
$3.78

Technical Indicators

Market Signals
Indicator
BIOX
ALLO
Relative Strength Index (RSI) 40.55 51.73
Support Level $1.40 $1.38
Resistance Level $1.65 $1.57
Average True Range (ATR) 0.11 0.10
MACD -0.02 -0.01
Stochastic Oscillator 10.47 43.40

Price Performance

Historical Comparison
BIOX
ALLO

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: